Go Back

RA Capital Management

RA Capital Management, a venture fund based in Boston, Massachusetts, was founded in 2001. Specializing in the healthcare, biotech, and AI/ML sectors, the fund invests across various stages from Pre-Seed to Series D. Partnered with Peter Kolchinsky, they have made 288 investments in companies like Somatus, Exo, and Element Biosciences, with 140 successful exits. RA Capital Management focuses on life sciences and drug development, with a diverse portfolio including startups such as GentiBio, Ceribell, and ViaCyte. For more information, visit their website at www.racap.com.

About

About

About

Bio

RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.

Location

Boston, Massachusetts

Stage

Pre-Seed, Seed, Series A, Series B, Series C, Series D

Partner name

Peter Kolchinsky

Bio

RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.

Location

Boston, Massachusetts

Stage

Pre-Seed, Seed, Series A, Series B, Series C, Series D

Partner name

Peter Kolchinsky

Fund

Fund

Fund

Fund Focus

Healthcare, Medical Device, Health & Wellness, BioTech, Life Science, Pharmaceuticals, Artificial Intelligence & Machine Learning (AI/ML)

Number of investments

288

Number of exits

140

Fund Type

Venture Fund

Portfolio Companies

Somatus, Exo, Element Biosciences, Mineralys Therapeutics, Sionna Therapeutics, GentiBio, Boundless Bio, Artiva Biotherapeutics, Frontier Medicines, Ceribell, Be Biopharma, Scribe Therapeutics, Tasso, Antios Therapeutics, Acrivon Therapeutics, Cedilla Therapeutics, Curie Therapeutics, Locanabio, Plexium, Obsidian Therapeutics, Electra Therapeutics, ViaCyte, Synthekine, Asher Bio, Jnana Therapeutics, DTx Pharma

RA Capital Management

RA Capital Management, a venture fund based in Boston, Massachusetts, was founded in 2001. Specializing in the healthcare, biotech, and AI/ML sectors, the fund invests across various stages from Pre-Seed to Series D. Partnered with Peter Kolchinsky, they have made 288 investments in companies like Somatus, Exo, and Element Biosciences, with 140 successful exits. RA Capital Management focuses on life sciences and drug development, with a diverse portfolio including startups such as GentiBio, Ceribell, and ViaCyte. For more information, visit their website at www.racap.com.

About

Bio

RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.

Location

Boston, Massachusetts

Stage

Pre-Seed, Seed, Series A, Series B, Series C, Series D

Partner name

Peter Kolchinsky

Fund

Fund Focus

Healthcare, Medical Device, Health & Wellness, BioTech, Life Science, Pharmaceuticals, Artificial Intelligence & Machine Learning (AI/ML)

Number of investments

288

Number of exits

140

Fund Type

Venture Fund

Portfolio Companies

Somatus, Exo, Element Biosciences, Mineralys Therapeutics, Sionna Therapeutics, GentiBio, Boundless Bio, Artiva Biotherapeutics, Frontier Medicines, Ceribell, Be Biopharma, Scribe Therapeutics, Tasso, Antios Therapeutics, Acrivon Therapeutics, Cedilla Therapeutics, Curie Therapeutics, Locanabio, Plexium, Obsidian Therapeutics, Electra Therapeutics, ViaCyte, Synthekine, Asher Bio, Jnana Therapeutics, DTx Pharma